A Retrospective Study on the Association of Has-Bled Score with Risk of Gastrointestinal Bleeding Among Patients on Warfarin in Hospital Pakar Universiti Sains Malaysia

Nurshafira Kamarulzaman, W.Yus Haniff W. Isa, Amry A. Rahim

Abstract


Warfarin is widely used in developing countries because of its low cost and availability compared to other novel oral anticoagulants. Early prevention of anticoagulant complications such as major bleeding, particularly gastrointestinal bleeding (GIB), is essential. In Malaysia, sufficient data on the occurrence and risk factors of GIB in individuals receiving warfarin are lacking. Objectives: To evaluate the efficacy of the HAS-BLED score in prognosticating GIB events in patients who underwent warfarin therapy at Hospital USM. Methodology: In this retrospective study, patients receiving warfarin at Hospital USM between January 2017 and December 2021 were categorised as high-risk (HAS-BLED score ≥ 3) or non-high-risk (HAS-BLED score ≤ 2) based on their medical data. The association between the HAS-BLED score and the occurrence of GIB was determined using simple logistic regression. Results: Data on 138 individuals were gathered, and 25 patients (18.1%) were found to have experienced GIB. The number of patients who had a GIB event during or after six months of warfarin therapy was 16 and 9, respectively. Of the high-risk group, 24 patients (96.0%) had experienced GIB, while only one non-high-risk group member had experienced a GIB event. The results of this study suggest a significant association between HAS-BLED score and GIB events (P<0.005). Conclusion: This novel bleeding risk score adequately stratifies GIB risk and predicts GIB events among patients who have received warfarin. In this study, inclusion in the high-risk group was associated with increased GIB events.


Keywords


Gastrointestinal bleeding, warfarin, HAS-BLED

Full Text:

PDF

References


Lee SJ, Uhm JS, Kim JY, Pak HN, Lee MH, Joung B. The safety and efficacy of vitamin K antagonist in patients with atrial fibrillation and liver cirrhosis. Int J Cardiol. 2015 Feb 1;180:185-91. doi: 10.1016/j.ijcard.2014.11.183.

Rockall TA, Logan RF, Devlin HB, Northfield TC. Incidence of and mortality from acute upper gastrointestinal haemorrhage in the United Kingdom. Steering Committee and members of the National Audit of Acute Upper Gastrointestinal Haemorrhage. BMJ. 1995 Jul 22;311(6999):222-6. doi: 10.1136/bmj.311.6999.222.

Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010 Nov;138(5):1093-100. doi: 10.1378/chest.10-0134.

Beltrame, R. C. F., Giasson, F. T. B., Silva, A. L. F. A. da et al,Use of HAS-BLED Score in an Anticoagulation Outpatient Clinic of a Tertiary Hospital. International Journal of Cardiovascular Sciences, 2017: 30(6), 517–525. doi:10.5935/2359-4802.20170081

Chang G, Xie Q, Ma L, Hu K, Zhang Z, Mu G, Cui Y. Accuracy of HAS-BLED and other bleeding risk assessment tools in predicting major bleeding events in atrial fibrillation: A network meta-analysis. J Thromb Haemost. 2020 Apr;18(4):791-801. doi: 10.1111/jth.14692.

Lee SL, Ong TJ, Mazlan-Kepli W, Mageswaran A, Tan KH, Abd-Malek AM et al,Patients' time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic. World J Cardiol. 2021 Sep 26;13(9):483-492. doi: 10.4330/wjc.v13.i9.483.

Chen WC, Chen YH, Hsu PI, Tsay FW, Chan HH, Cheng JS, Lai KH. Gastrointestinal hemorrhage in warfarin anticoagulated patients: incidence, risk factor, management, and outcome. Biomed Res Int. 2014;2014:463767. doi: 10.1155/2014/463767.

Kim BS, Li BT, Engel A, Samra JS, Clarke S, Norton ID, Li AE. Diagnosis of gastrointestinal bleeding: A practical guide for clinicians. World J Gastrointest Pathophysiol. 2014 Nov 15;5(4):467-78. doi: 10.4291/wjgp.v5.i4.467.

Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14;123(23):2736-47. doi: 10.1161/CIRCULATIONAHA.110.009449

Kooiman J, van Hagen N, Iglesias Del Sol A, Planken EV, Lip GY, van der Meer FJ et al, The HAS-BLED Score Identifies Patients with Acute Venous Thromboembolism at High Risk of Major Bleeding Complications during the First Six Months of Anticoagulant Treatment. PLoS One. 2015 Apr 23;10(4):e0122520. doi: 10.1371/journal.pone.0122520.

Chan, Pak Hei,Wen-Hua Li, Jo-Jo Hai, Koon-Ho Chan, Hung-Fat Tse et al,“Gastrointestinal Haemorrhage in Atrial Fibrillation Patients: Impact of Quality of Anticoagulation Control.” European Heart Journal - Cardiovascular Pharmacotherapy 1(4): 2015: 265–72. doi:10.1093/ehjcvp/pvv032

Jun M, James MT, Manns BJ, Quinn RR, Ravani P, Tonelli M et al,The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. BMJ. 2015 Feb 3;350:h246. doi: 10.1136/bmj.h246.

Tang J, Sharma U, Desai S, Molnar J, Perlmuter L, Feller A et al,Study of Proton Pump Inhibitors and Other Risk Factors in Warfarin-Associated Gastrointestinal Bleeding. Cureus. 2021 Jan 11;13(1):e12624. doi: 10.7759/cureus.12624.

Patel P, Pandya J, Goldberg M. NOACs vs. Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation. Cureus. 2017 Jun 26;9(6):e1395. doi: 10.7759/cureus.1395.




Copyright (c) 2024 Journal of Biomedical and Clinical Sciences (JBCS)

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

Flag Counter           

                     

                                              Copyright © 2016 AMDI Publisher, Universiti Sains Malaysia.
Disclaimer : This website has been updated to the best of our knowledge to be accurate. However, Universiti Sains Malaysia shall not be liable for any loss or damage caused by the usage of any information obtained from this web site.
                                            Best viewed: Mozilla Firefox 4.0 & Google Chrome at 1024 × 768 resolution.